1 resultado para renin

em Chinese Academy of Sciences Institutional Repositories Grid Portal


Relevância:

10.00% 10.00%

Publicador:

Resumo:

Ang II受体拮抗剂是作用于肾素-血管紧张素系统(RAS)的抗高血压药,因其抗高血压作用与较老的抗高血压药物作用相同,且更具有选择性,不良反应状况与安慰剂相似,而在高血压治疗中逐渐引起研究者重视,并成为目前增长最快的抗高血压药物。在许多AngII受体拮抗剂中四氮唑结构已成为固定基团,但四氮唑有许多合成及代谢弊端。因此,寻找其他合适的杂环酸性基团来替代四氮唑,在保持较高口服活性的同时克服相应缺陷,具有极其重要的意义。 本项目以四氮唑沙坦类药物为先导化合物,运用生物电子等排原理及拼合原理,根据计算机分子模拟研究结果,对其进行结构修饰和改造,首次将咪唑、氯代咪唑、三氮唑及咪唑啉替代四氮唑,并结合具有较高AngII受体拮抗活性的联苯并咪唑衍生物,设计并合成一系列含咪唑,咪唑啉,氯代咪唑及三氮唑衍生物的Ang II受体拮抗剂。 研究这一系列新型AngII受体拮抗剂的体内、体外抗高血压活性时,发现咪唑啉衍生物展示了与对照药物几乎相当的活性,而咪唑、氯代咪唑和三氮唑衍生物分别表现了较弱或者没有活性,这些研究对今后更进一步设计合成新的Ang II受体拮抗剂具有重要的指导意义,同时也为筛选抗高血压药物奠定良好的基础。 The angiotensin II receptor antagonists act on renin-angiotensin system (RAS), which are as effective as other types of anti-hypertensive drugs. Because even the more specific and comparable to placebo in terms of side effects, Ang II receptor antagonists cause a high attention and become the fastest growing anti-hypertension drugs. Most of such compounds share the biphenyltetrazole unit with the lead Losartan. However, there are many defects in tetrazole synthesis and vivo metabolism. Therefore, we felt quite encouraged to find some proper acidic heterocyclic groups which maintain the same oral bioavailability to replace the tetrazole. In the present paper, we applied the bioisostere and combination principle, in accordance with the results of computer modeling of molecular, to modify the lead structural of terazole in sartan compounds reported. We turned our attention to replace the tetrazole ring with imidazole rings, chloro-imidazole, imidazoline, traizole ring and combinated them with benzimidazoles derivatives which have antagonistic activity for angiotensin II to design and synthesize a series of Ang II receptor antagonists contaning imidazole ring, chloro-imidazole, imidazoline or traizole ring. In addition, activity tests in vivo and in vivo had shown that imidazoline derivatives display almost equivalent activity with the reference drug, but imidazole derivatives, chloro-imidazole, triazole derivatives were weak or non-performance of the hypotensive activity. We believe that the imidazoline derivative type Ang II receptor antagonists can build a foundation for the development of a novel series of anti-hypertensive drugs.